Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy.

Background: The treatment of carcinoma of unknown primary based on histopathology and immunohistochemistry is generally chemotherapy. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation.

Case Report: We report the case of a 56-year-old patient who presented to medical attention with palpable axillary adenopathy.